Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 10:19 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,933 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Lipid Disorder Clear all
Completed No phase listed Observational Accepts healthy volunteers

Exploration of Immunity in Gaucher Disease

NCT01358188
View directory record Official record
Conditions
Gaucher Disease
Interventions
Not listed
Lead sponsor
O & O Alpan LLC
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 2 Interventional

Study on the Safety and Effects on Lipids of FM-VP4 in Subjects With Primary Hypercholesterolemia

NCT00293878
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)
Drug
Lead sponsor
Forbes Medi-Tech
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Timeline
Started 2005
U.S. locations
14
States / cities
Mobile, Alabama • San Diego, California • Daytona Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2007 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 1 Interventional

The Influence of Ritonavir, Alone and in Combination With Lopinavir, on Fenofibric Acid Pharmacokinetics in Healthy Volunteers

NCT01148004
View directory record Official record
Conditions
HIV, Fenofibrate, Protease Inhibitors, Hypertriglyceridemia, Glucuronosyltransferase
Interventions
Fenofibrate, Ritonavir, Lopinavir/Ritonavir
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

NCT05261126
View directory record Official record
Conditions
Hypercholesterolemia, Familial Hypercholesterolemia
Interventions
Enclitide Chloride, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
20
States / cities
Beverly Hills, California • Sacramento, California • Santa Ana, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2024 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Not applicable Interventional

The CREATE Wellness Study

NCT02302612
View directory record Official record
Conditions
Diabetes, Heart Disease, Hypertension, Dyslipidemia
Interventions
CREATE Wellness, Usual Care Control
Behavioral · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
40 Years to 85 Years
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 27, 2026, 10:19 AM EDT
Recruiting Phase 2 Interventional

2-Hydroxybenzylamine (2-HOBA) to Reduce HDL Modification and Improve HDL Function in Familial Hypercholesterolemia (FH)

NCT04941599
View directory record Official record
Conditions
Familial Hypercholesterolemia
Interventions
2-Hydroxybenzylamine, Placebo
Drug · Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Relative Bioavailability of Two Iberdomide (CC-220) Formulations and to Assess The Effect Of Food on the Drug Levels of Iberdomide in Healthy Adult Participants

NCT05899738
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Iberdomide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 27, 2026, 10:19 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Submental Study (Sequential Treatment Approach)

NCT03510598
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The ZELTIQ CoolSculpting System, Kybella 20 MG in 2 ML Injection
Device · Drug
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
22 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2021 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety

NCT03689738
View directory record Official record
Conditions
Insulin Sensitivity, Lipid Metabolism, Resistant Starch, Potato
Interventions
Potato (Resistant Starch), CHO-matched (Low-fiber, RS-free)
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 27, 2026, 10:19 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

NCT06894004
View directory record Official record
Conditions
Hypercholesterolemia and Hyperlipidemia
Interventions
Ketogenic Diet, Control Diet
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 39 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects

NCT01486433
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Simvastatin, acetylsalicylic acid (ASA), omefas
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 27, 2026, 10:19 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Lovaza in Adolescents With Mild to Moderately Elevated Triglycerides

NCT00672633
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Lovaza, Placebo
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
10 Years to 19 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 27, 2026, 10:19 AM EDT
Completed No phase listed Observational

Study of Smith-Lemli-Opitz Syndrome

NCT00001721
View directory record Official record
Conditions
Smith-Lemli-Opitz Syndrome
Interventions
Cholesterol Suspension, CRH, Cholesterol
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Not listed
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 27, 2026, 10:19 AM EDT
Active, not recruiting No phase listed Observational

Biological Sample Repository for Gastrointestinal Disorders

NCT05874726
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Obesity, Primary, Gastro-Intestinal Disorder, Overweight and Obesity, Overweight, Overweight or Obesity, Diabetes Type 2, Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension, Hyperlipidemias, Sleep Apnea, GERD, Gastroesophageal Reflux, Musculoskeletal Pain Disorder, Cancer
Interventions
Blood Collection, Urine Collection, Tissue Sample Collection
Diagnostic Test
Lead sponsor
Pichamol Jirapinyo, MD, MPH
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 27, 2026, 10:19 AM EDT
Terminated Phase 3 Interventional Results available

Study of the Use of Niaspan for Treatment of Dyslipidemia in Diabetic Nephropathy

NCT00108485
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Kidney Failure, Chronic, Hyperlipidemia
Interventions
Extended release niacin, Placebo
Drug · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 1 Interventional Results available

A Gene Therapy Study in Patients With Gaucher Disease Type 1

NCT05324943
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
FLT201
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fat Burning After a Meal

NCT02211599
View directory record Official record
Conditions
Postprandial Effect of Carbohydrate Beverage Consumption
Interventions
15% protein, 30% protein, Sweetened beverage
Other
Lead sponsor
USDA Grand Forks Human Nutrition Research Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Grand Forks, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2022 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)

NCT02666664
View directory record Official record
Conditions
Hypercholesterolemia, Atherosclerotic Cardiovascular Diseases
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
48
States / cities
Huntsville, Alabama • Cottonwood, Arizona • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated May 11, 2020 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Soy Supplementation and Gestational Diabetes

NCT02806739
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Soy Group (Soy Protein + Isoflavones), Control Group (Minimize Soy Intake)
Dietary Supplement
Lead sponsor
University of Massachusetts, Boston
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Placebo-Controlled Study of Leptin for the Treatment of HIV Lipodystrophy and Metabolic Syndrome

NCT00140244
View directory record Official record
Conditions
HAART-induced Lipodystrophy and Metabolic Syndrome
Interventions
r-metHuLeptin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Oct 27, 2026, 10:19 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Postprandial Monocyte Maturation and Vascular Dysfunction Following High-Fat Meals - Study 1

NCT03958734
View directory record Official record
Conditions
Cardiovascular Risk Factor, Lipemia
Interventions
High-fat meal
Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 30 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 27, 2026, 10:19 AM EDT
Terminated Not applicable Interventional

Nutritional Treatment of Overweight Adolescents With Cardiovascular Risk Factors (PowerUp)

NCT00477477
View directory record Official record
Conditions
Childhood Obesity, Dyslipidemia, Insulin Resistance, Hypertension
Interventions
Diet
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 27, 2026, 10:19 AM EDT
Enrolling by invitation No phase listed Observational

Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)

NCT00983463
View directory record Official record
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Not listed
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 27, 2026, 10:19 AM EDT